Please login to the form below

Not currently logged in
Email:
Password:

gilteritinib

This page shows the latest gilteritinib news and features for those working in and with pharma, biotech and healthcare.

NICE recommends Astellas’ Xospata for NHS use

NICE recommends Astellas’ Xospata for NHS use

At the beginning of the year, NICE rejected Xospata (gilteritinib) citing uncertainty around the long-term survival benefit of the drug in FLT3-positive acute myeloid leukaemia (AML) patients as grounds

Latest news

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics